Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Heparin Lock Flush (obsolete), Hep-Lock (obsolete), Hep-Pak (obsolete), Hep-Pak CVC (obsolete), Heparin Sodium ADD (Vantage) 
Synonyms :
heparin
Class :
Anticoagulants, Hematologic; Anticoagulants, Cardiovascular 
Brand Name :
Heparin Lock Flush (obsolete), Hep-Lock (obsolete), Hep-Pak (obsolete), Hep-Pak CVC (obsolete), Heparin Sodium ADD (Vantage) 
Synonyms :
heparin
Class :
Anticoagulants, Hematologic; Anticoagulants, Cardiovascular 
Dosage Forms & Strengths Â
heparin lock solution Â
100units/mL Â
10units/mL Â
2units/mL Â
1unit/mL Â
premixed IV solution Â
25,000units/500mL Â
25,000units/250mL Â
20,000units/500mL Â
12,500units/250mL Â
injectable solution Â
20,000units/mL Â
10,000units/mL Â
5000units/mL Â
2500units/mL Â
1000units/mL Â
Prophylaxis
7500 units subcutaneous every 12 hours, OR
5000 units subcutaneous every 8-12hours
Treatment
Intravenous bolus of 80 units/kg, following continuous infusion of about 18 units/kg in hour, OR
subcutaneous injection 250 units/kg, following 250 units/kg for every 12 hours
5000 units Intravenous bolus, following continuous infusion of 1300 units/hr, OR
Dosing considerations
There are a number of concentrations available; caution is necessary to prevent the medication errors
Intermittent intravenous injection
8000-10,000 units intravenous initially, following 50-70 units/kg (5000-10,000 units) every 4-6 hours
Continuous intravenous infusion
5000 units intravenous injection, then by continuous intravenous infusion of 20,000-40,000 units/24 hours
Dosing considerations
There are several concentrations available; extreme caution is necessary to prevent a medication error
When heparin is administered with warfarin sodium or dicumarol, a delay of 24 hours after the last subcutaneous dose or 5 hours after the last intravenous dose should be given before blood is collected if a prothrombin time is achieved.
PCI
Without the GPIIb or IIIa inhibitor: 70 to 100 unit/kg Intravenous bolus initially
With GPIIb or IIIa inhibitor: 50 to 70 units/kg Intravenous bolus initially
STEMI
Patient who are on fibrinolytics: IV bolus of 60 units/kg (maximum: 4000 units), following 12 units/kg in hour as continuous IV infusion (max 1000 units/hr)
The dose must be adjusted to keep the aPTT between 50 to 70 seconds
NSTEMI/Unstable Angina
6 to 70 units/kg intravenous bolus initially (maximum: 5000 units), following 12-15 units/kg in hour intravenous infusion initially (maximum: 1000 units/hr)
The dose must be adjusted to keep the aPTT between 50 to 70 secs
Dosing considerations
There are several concentrations available; extreme caution is necessary to prevent a medication error
Catheter Patency
Clot prevention in arterial and venous catheters
Use 100 units/mL; inject enough fluid to fill the catheter's lumen.
Dosing considerations
There are several concentrations available; caution is necessary to prevent a medication errors.
The amount and frequency are determined by the catheter capacity and type.
Peripheral heparin locks are normally flushed every 6-8 hours
Dose Adjustments
Dosing Modifications
Hepatic impairment: use Caution; dose adjustment is required
Catheter Patency
Clot prevention in arterial and venous catheters
Use 100 units/mL; inject enough fluid to fill the catheter's lumen.
Dosing considerations
There are several concentrations available; caution is necessary to prevent a medication errors.
The amount and frequency are determined by the catheter capacity and type.
Peripheral heparin locks are normally flushed every 6-8 hours
Dose Adjustments
Dosing Modifications
Hepatic impairment: use Caution; dose adjustment is required
Dosage Forms & Strengths Â
injectable solution Â
10,000units/mL Â
5000units/mL Â
1000units/mL Â
heparin lock solution Â
100units/mL Â
10units/mL Â
Refer to the adult dosing regimen Â
may have an increased anticoagulant effect when combined with Heparin
may have an increased anticoagulant effect when combined with Heparin
may have an increased anticoagulant effect when combined with Heparin
may have an increased anticoagulant effect when combined with Heparin
may have an increased anticoagulant effect when combined with Heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
heparin: it may enhance the toxic effect of Anti-Inflammatory Agents
heparin: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
heparin: it may enhance the toxic effect of Anti-Inflammatory Agents
heparin: it may enhance the toxic effect of Anti-Inflammatory Agents
heparin: it may enhance the toxic effect of Anti-Inflammatory Agents
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may increase the anti-coagulant effect of anti-platelet agents
may increase the anti-coagulant effect of antiplatelet agents
may increase the anti-coagulant effect of nonsteroidal anti-inflammatory agents
may increase the anticoagulation effect when combined
desirubin: they may increase the anticoagulant effect of anticoagulants
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
due to anticoagulant properties of taheebo, other anticoagulant use is contraindicated
use caution when bladderwrack is used in combination with anticoagulant medication due to antiplatelet action
bloodroot along with anticoagulant medications will result in bleeding and bruising
when combined, may increase anticoagulation
may have an increased anticoagulant effect when combined with heparin
may decrease the therapeutic effect when combined with heparin
piperacillin will increase the effectiveness of heparin by anticoagulation
when both drugs are combined, there may be an increased effect of heparin by anticoagulation  
when both drugs are combined, there may be an increased effect of heparin by anticoagulation  
azithromycin decreases the metabolism of heparin and increases its effect
may enhance the toxicity of the other through anti coagulation
may enhance the effect of anticoagulants
edoxaban increases the effect of anticoagulants
it increases the toxicity of anticoagulants
anticoagulants increase the toxicity of omacetaxine
vorapaxar increases the toxicity of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with corticorelin
may decrease the therapeutic effect when combined with heparin
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased thrombogenic effect when combined with anti- coagulant inhibitor complex
urokinase: they may increase the anticoagulant effect of anticoagulants
the activity of heparin is reduced by butabarbital by enhancing metabolism
thrombolytic Agents may enhance the anticoagulant effect of anticoagulants
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it increases the effect of hyperkalemia of angiotensin II receptor blockers
it increases the effect of hyperkalemia of angiotensin II receptor blockers
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased hyperkalemic effect when combined with aliskiren
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with eplerenone
may diminish the serum concentration when combined with levothyroxine
may enhance the serum concentration when combined with palifermin
may have an increased anticoagulant effect when combined with heparin
spironolactone and hydrochlorothiazide
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
It may enhance the toxicity when combined with mipomersen
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
nonsteroidal anti-Inflammatory agents may strengthen the anticoagulant effects of anticoagulants
antiplatelet agents increase the effect of anticoagulants
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
It may diminish the metabolism when combined with Heparins
It may diminish the metabolism when combined with Heparins
It may diminish the metabolism when combined with Heparins
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
It may enhance the risk of adverse effects when combined with Anticoagulants
spironolactone and hydrochlorothiazide
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with potassium salts
heparin: it may decrease the therapeutic efficacy of soyabean oil
both forskolin and heparin enhance anticoagulation
reduce therapeutic effects of heparin
gemcitabine, by the unspecific reactions, increases the effect of heparin
the effect of heparin is increased by fluorouracil with the help of an unspecific interaction mechanism
it increases the effect of hyperkalemia in potassium salts
it may increase the action of anticoagulant effect
it may increase the effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
choline magnesium trisalicylate
salicylates may enhance the anticoagulant effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the toxic effect of prostacyclin analogs
may enhance the anticoagulant effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may increase the anti-platelet effect of anti-coagulants agents
may have an increased anticoagulant effect when combined with Anticoagulants
bromeperidol increases the toxicity of anticoagulants
it increases the effect of anticoagulants
may enhance the nephrotoxic effect of salicylates
may have an increased adverse effect when combined with anticoagulants
may have an increased adverse effect when combined with anticoagulants
may have an increased adverse effect when combined with anticoagulants
may have an increased adverse effect when combined with ibritumomab tiuxetan
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may enhance the effect of anticoagulants
may increase the anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with deferasirox
may have an increasingly adverse effect when combined with deoxycholic acid
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may have an increasingly adverse effect when combined with nintedanib
may decrease the anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with obinutuzumab
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may reduce the anticoagulant effect
may reduce the anticoagulant effect
choline magnesium trisalicylate
may enhance the anticoagulant effect
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may decrease the therapeutic effect of factor X
may have an increasingly adverse effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increasingly adverse effect when combined with anticoagulants
may enhance the serum concentration of palifermin
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the anticoagulant effects of each other when combined
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may increase the anticoagulant effect when combined
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
It may enhance the risk of adverse effects when combined with Respiratory Stimulants
may increase the risk of haemorrhage with oral anticoagulants
may increase the risk of haemorrhage with oral anticoagulants
may increase the risk of haemorrhage with oral anticoagulants
eplerenone: they may increase the anticoagulant effect of anticoagulants
vitamin E: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j3: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
corticosteroids j4: they may increase the anticoagulant effect of anticoagulants
ceritinib: they may increase the anticoagulant effect of anticoagulants
The anticoagulant effects of ancord may be enhanced when administered concomitantly with other anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
other antiplatelet agents increase the anticoagulative effect of heparin
other antiplatelet agents increase the anticoagulative effect of heparin
demeclocycline increases the effects of heparin by an unknown mechanism
doxycycline increases the effects of heparin by an unknown mechanism
caplacizumab has the potential to increase the anticoagulant activity of other anticoagulants
Actions and Spectrum:
Heparin is a naturally occurring anticoagulant in the blood that enhances the action of the antithrombin III that inhibits the blood clot. Â
Heparin is a powerful anticoagulant and is used in different pathologic states involving formation of blood clots, like postoperative state, deep vein thrombosis, pulmonary embolism and myocardial infarction. It is also used in surgeries involving heart bypass, and dialysis to avert the formation of blood clots. Moreover, it is employed as a preventive agent in high cardiovascular risk patients who have atrial fibrillation and as the therapy for patients with DIC and the antiphospholipid syndrome.
Frequency defined Â
>10% Â
Possibly delayed, Heparin-induced thrombocytopenia (10-30%) Â
Frequency not defined Â
Hemorrhage Â
Increased liver aminotransferase Â
Immune hypersensitivity reaction Â
Mild pain Â
Injection site ulcer Â
Anaphylaxis Â
Osteoporosis Â
Post marketing Reports Â
Gasping syndrome Â
Necrosis of skin Â
serious adverse reactions Â
Vascular disorders, including vasospastic reactions, contusion Â
Delayed transient alopecia Â
Rebound hyperlipemia Â
heparin resistance Â
Hypersensitivity Â
Local irritation, mild pain, ulceration or hematoma, erythema Â
Histamine-like reactions Â
Hyperkalemia Â
Priapism Â
Black Box Warning
History of bleeding. Â
Contraindication /Caution Â
Contraindication: Â
Known hypersensitivity to heparin or pork products (heparin is derived from porcine intestinal mucosa) Â
Active major bleeding or conditions with a high risk of hemorrhage Â
Severe thrombocytopenia (platelet count < 100,000/mm3) Â
Uncontrolled arterial hypertension Â
Intracranial hemorrhage (except when caused by anticoagulants) Â
Bacterial endocarditis or other systemic infections Â
Severe liver or kidney disease Â
Recent eye, brain, or spinal cord surgery or lumbar puncture Â
Caution: Â
Active bleeding or a history of bleeding disorders Â
Severe hypertension Â
Severe liver or kidney disease Â
Recent surgery or trauma Â
Bacterial endocarditis Â
Diabetes mellitus Â
Eye or brain surgery Â
Ulcerative colitis Â
Elderly patients Â
Women who are pregnant or breastfeeding Â
Pregnancy/Lactation  Â
Pregnancy consideration: US FDA pregnancy category: Not assigned Â
Lactation: Heparin is not known whether it is excreted into human milk Â
Pregnancy category: Â
Pharmacology:Â
Heparin is a sulfate rich glycosaminoglycan, it is well known anticoagulant, since it binds to antithrombin III (serine protease inhibitor) that inactivates thrombin and factor Xa.Â
Pharmacodynamics: Â
Heparin makes use of antithrombin III thus enhancing the inhibitory activity of clotting factors such as thrombin and factor Xa. Upon binding to heparin, heparin induces conformational changes that increase facilitated the inhibitory effects of antithrombin III toward thrombin and factor Xa. This results in the anticlotting action that prevents the change from fibrinogen to fibrin and blood clotting.
The heparin crucial characteristics is its prompt action; it starts acting right after injection and within several minutes. Regarding its anticoagulant effect, the level of the efficacy may be assessed by activated partial thromboplastin time (aPTT) or anti-factor Xa activity. Depending on the dosage and mode of administration, its anticoagulant action has varying durations. Â
Pharmacokinetics: Â
Absorption Â
when administered subcutaneously, heparin has a slow and partial absorption in the systemic circulation. The reaction begins after several days and is dose and site dependent. Heparin therapy levels are immediately achieved with intravenous injection.Â
Distribution Â
Heparin distributes in small volume since it binds with high affinity to plasma proteins such as antithrombin III. It does not cross the blood-brain barrier.Â
Metabolism Â
Heparin is not biotransformed in the liver or other organs.Â
Elimination and excretion Â
The reticuloendothelial system and, to a lesser extent, the kidneys remove heparin from the bloodstream. Heparin’s elimination half-life varies from 30 minutes to 2 hours and is dependent on dosage. Â
Administration  Â
Heparin can be given intravenously, subcutaneously and as a continuous infusion. Choosing the route of administration depends on the intended purpose and the duration of the effect that is expected. Â
Regarding the dosage and administration of heparin, it may differ depending on certain aspects: weight, age, as well as specific medical conditions. Â
Patient information leaflet Â
Generic Name: heparin Â
Pronounced: [ HEP-a-rin ]Â
Why do we use heparin? Â
Heparin is employed for the purpose of anticoagulation, or the prevention of formation of blood clots. This can be used to treat and prevent disorders like pulmonary embolism and deep vein thrombosis in patients at high risk including those that are restricted to bed rest or have undergone surgery. Â
Heparin is also used for treatment of certain types of acute myocardial infarction and unstable angina and as an anticoagulant for patients undergoing specific procedures like haemodialysis and blood transfusion. Also, heparin can help prevent possible blood clotting in people with atrial fibrillation or mechanical heart valves.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
